0.653

5.32% 0.033

After Hours: .63 -0.023 -3.52%

Athira Pharma Inc (ATHA)

Overview News Price History Option Chain Financials Discussions Forecast

Athira Pharma Inc stock is traded at $0.653, with a volume of 404.98K. It is up +5.32% in the last 24 hours and up +39.59% over the past month. Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Previous Close:

$0.62

Open:

$0.61

24h Volume:

404.98K

Relative Volume:

0.08

Market Cap:

$23.97M

Revenue:

Net Income/Loss:

$-117.67M

P/E Ratio:

-0.2307

EPS:

-2.83

Net Cash Flow:

$-101.06M

1W Performance:

+1.67%

1M Performance:

+39.59%

6M Performance:

-75.27%

1Y Performance:

-57.32%

1-Day Range:

$0.61

$0.67

1-Week Range:

$0.61

$0.70

52-Week Range:

$0.4115

$4.2984

Athira Pharma Inc Stock (ATHA) Company Profile

Name

Athira Pharma Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(425) 620-8501

Address

18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL

Employee

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

ATHA's Discussions on Twitter

Compare ATHA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATHA Athira Pharma Inc	0.653	23.97M	0	-117.67M	-101.06M	-2.83
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Jul-07-22	Initiated	Mizuho	Buy
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold
Jun-23-22	Downgrade	Stifel	Buy → Hold
May-10-22	Initiated	BTIG Research	Buy
Apr-21-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Goldman	Neutral
Oct-13-20	Initiated	Goldman	Buy
Oct-13-20	Initiated	JMP Securities	Mkt Outperform
Oct-13-20	Initiated	Jefferies	Buy
Oct-13-20	Initiated	Stifel	Buy

View All

Athira Pharma Inc Stock (ATHA) Latest News

Nov 25, 2024

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by GSA Capital Partners LLP - Defense World

Nov 25, 2024

Nov 12, 2024

Athira Pharma's SWOT analysis: stock shifts focus after trial setback By Investing.com - Investing.com UK

Nov 12, 2024

Athira Pharma's SWOT analysis: stock shifts focus after trial setback - Investing.com

Nov 12, 2024

Nov 11, 2024

Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline - MSN

Nov 11, 2024

Nov 08, 2024

Athira exploring strategic alternatives after Alzheimer’s failure - BioPharma Dive

Nov 08, 2024

Athira Pharma Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024

Nov 07, 2024

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - The Manila Times

Nov 07, 2024

Nov 05, 2024

What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register

Nov 05, 2024

Nov 04, 2024

Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360

Nov 04, 2024

US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St

Nov 04, 2024

Nov 01, 2024

Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga

Nov 01, 2024

Oct 31, 2024

Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com

Oct 31, 2024

Oct 26, 2024

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN

Oct 26, 2024

Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire

Oct 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan

Oct 22, 2024

Oct 18, 2024

Athira Pharma faces Nasdaq delisting over share price - Investing.com

Oct 18, 2024

Oct 16, 2024

A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News

Oct 16, 2024

Oct 07, 2024

A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News

Oct 07, 2024

A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily

Oct 07, 2024

Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex

Oct 07, 2024

Sep 29, 2024

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World

Sep 29, 2024

Sep 27, 2024

Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com

Sep 27, 2024